H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme Therapeutics to $50 from $48 and keeps a Buy rating on the shares. The analyst says more share buybacks in store after another solid quarter from the company. Halozyme holds $336M in cash, which is sufficient to fund operations going forward as the company is currently profitable, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO:
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
- Halozyme announces Takeda received EC approval for HYQVIA
- Halozyme announces approval for Vydura in Japan
- Halozyme price target lowered to $48 from $61 at H.C. Wainwright
- Halozyme: Takeda receives FDA approval of HYQVIA co-formulated with ENHANZE
